A glitch in the ability to move iron around in cells may underlie a disease known as Type IV mucolipidosis (ML4) and the suite of symptoms —mental retardation, poor vision and diminished motor abilities — that accompany it, research shows.
The same deficit also may be involved in aging and neurodegenerative diseases such as Alzheimer’s and Parkinson’s, says Haoxing Xu, assistant professor of molecular, cellular and developmental biology.
The findings appear online in the journal Nature.
An interest in iron transport led Xu to investigate ML4, another symptom of which is iron-deficiency anemia. Perhaps, he and his collaborators reasoned, impaired iron transport could explain both the anemia and the other problems that go hand-in-hand with ML4, a genetic disorder that mainly affects Jews of Eastern European background. Children with ML4 begin showing signs of developmental delay and eye problems during the first year of life and typically fail to progress beyond the level of a 15-month-old. The disease is rare, but recent discovery of some children with milder forms raises the possibility of additional undiagnosed cases.
To explore the possible role of iron transport in the disease, Xu’s group focused on a protein called TRPML1. A mutation in the gene that produces TRPML1 is known to cause ML4, so the protein seemed like a logical starting point for investigating mechanisms responsible for the disease, even though TRPML1 had never been shown to be involved in iron transport. The only protein with that distinction was DMT1, which facilitates iron uptake in the gut and in cells that will become red blood cells, but not in most other cell types.
“Essentially all cells, including nerve cells and muscle cells, need iron,” Xu says. “We wondered what happens in those cells where DMT1 isn’t found, and we thought there must be an unidentified iron transporter protein, possibly TRPML1.”
TRPML1 isn’t the easiest protein to study. To probe the protein, Xu’s group had to modify a technique known as the patch clamp, in which a micropipette and electrodes are attached to a cell membrane to record the activity of individual or multiple proteins that serve as channels for charged particles (ions) moving in and out of cells.
They found that TRPML1 was indeed capable of ferrying iron out of the lysosome. But was there any evidence that interfering with that ability might result in ML4 symptoms? Xu’s group studied defective TRPML1 proteins bearing the same mutations as those found in ML4 patients. Mutations associated with severe symptoms were the least adept at shuttling iron, while those associated with milder symptoms were more proficient, although still not fully functional.
Further experiments confirmed that when TRPML1 is defective, iron becomes trapped in the lysosome. One result of the buildup is formation of a brownish waste material, lipofuscin. In skin cells, it is the culprit responsible for the dreaded liver spots, but in nerve, muscle and other cells, its accumulation has more serious consequences.
“How lipofuscin causes problems in neurons and muscles is not clear, but it’s believed that this is garbage that, in time, compromises the normal function of the lysosome,” Xu says. “And we know the lysosome is important for all kinds of cell biology, particularly the recycling of intracellular components, so if it’s damaged, the cell is going to suffer.” Abnormal accumulation of lipofuscin is associated with a range of disorders including Alzheimer’s disease, Parkinson’s disease, and macular degeneration, and also contributes to the aging process.
With connections among TRPML1, iron and lipofuscin coming into focus, researchers have new avenues to explore potential treatments.
Xu’s coauthors are postdoctoral fellows Xian-ping Dong and Xiping Cheng and undergraduate Eric Mills of U-M; Markus Delling of Children’s Hospital Boston; Fudi Wang of the Chinese Academy of Sciences and Tino Kurz of the University of Linköping, Sweden.
